HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer

Euan A. Stronach, Albandri Alfraidi, Nona Rama, Christoph Datler, James B. Studd, Roshan Agarwal, Tankut G. Guney, Charlie Gourley, Bryan T. Hennessy, Gordon B. Mills, Antonello Mai, Robert Brown, Roberto Dina, Hani Gabra

    Research output: Contribution to journalArticle

    107 Scopus citations

    Abstract

    Ovarian cancer frequently acquires resistance to platinum chemotherapy, representing a major challenge for improving patient survival. Recent work suggests that resistant clones exist within a larger drug-sensitive cell population prior to chemotherapy, implying that resistance is selected for rather than generated by treatment. We sought to compare clinically derived, intrapatient paired models of initial platinum response and subsequent resistant relapse to define molecular determinants of evolved resistance. Transcriptional analysis of a matched cell line series from three patients with high-grade serous ovarian cancer before and after development of clinical platinum resistance (PEO1/PEO4/PEO6, PEA1/PEA2, PEO14/PEO23) identified 91 up- and 126 downregulated genes common to acquired resistance. Significantly enhanced apoptotic response to platinum treatment in resistant cells was observed following knockdown of histone deacetylase (HDAC) 4, FOLR2, PIK3R1, or STAT1 (P < 0.05). Interestingly, HDAC4 and STAT1 were found to physically interact. Acetyl-STAT1 was detected in platinum-sensitive cells but not in HDAC4 overexpressing platinum-resistant cells from the same patient. In resistant cells, STAT1 phosphorylation/nuclear translocation was seen following platinum exposure, whereas silencing of HDAC4 increased acetyl-STAT1 levels, prevented platinum-induced STAT1 activation, and restored cisplatin sensitivity. Conversely, matched sensitive cells were refractory to STAT1 phosphorylation on platinum treatment. Analysis of 16 paired tumor biopsies taken before and after development of clinical platinum resistance showed significantly increased HDAC4 expression in resistant tumors [n = 7 of 16 (44%); P = 0.04]. Therefore, clinical selection of HDAC4-overexpressing tumor cells upon exposure to chemotherapy promotes STAT1 deacetylation and cancer cell survival. Together, our findings identify HDAC4 as a novel, therapeutically tractable target to counter platinum resistance in ovarian cancer.

    Original languageEnglish (US)
    Pages (from-to)4412-4422
    Number of pages11
    JournalCancer Research
    Volume71
    Issue number13
    DOIs
    StatePublished - Jul 1 2011

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Stronach, E. A., Alfraidi, A., Rama, N., Datler, C., Studd, J. B., Agarwal, R., Guney, T. G., Gourley, C., Hennessy, B. T., Mills, G. B., Mai, A., Brown, R., Dina, R., & Gabra, H. (2011). HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Research, 71(13), 4412-4422. https://doi.org/10.1158/0008-5472.CAN-10-4111